NCT05091528 - A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 8, 2022

Primary Completion Date

July 7, 2022

Study Completion Date

July 7, 2022

Conditions

HER2-positive Breast CancerHER2-positive Gastric CancerHER2-positive Colorectal CancerHER2-expressing Non-small Cell Lung Cancer

Interventions

DRUG

SBT6050

Dose range of 0.45 to 0.6 mg/kg by subcutaneous (SC) injection in 21-day cycles

DRUG

trastuzumab deruxtecan

5.4 mg/kg by intravenous (IV) infusion in 21-day cycles

DRUG

tucatinib

300 mg by mouth (PO) twice daily (BID)

DRUG

trastuzumab

8 mg/kg loading dose (first dose), then 6 mg/kg maintenance dose (subsequent doses) IV infusion in 21-day cycles

DRUG

capecitabine

1000 mg/m2 PO BID for 14 days of each 21-day cycle

DRUG

trastuzumab deruxtecan

6.4 mg/kg by IV infusion in 21-day cycles

Trial Locations (1)

Massachusetts General Hospital, Boston